Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Atuliflapon

Alternative Names: Atuliflapon, azd-5718, azd5718, azd 5718
Latest Update: 2025-04-15
Latest Update Note: Clinical Trial Update

Product Description

modifies coronary plaque volume for Acute Coronary Syndrome (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04601467)

Mechanisms of Action: 5-LOX Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Atuliflapon

Countries in Clinic: Argentina, Australia, Brazil, Bulgaria, Chile, Croatia, France, Germany, Hungary, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Poland, Romania, Serbia, Slovakia, Slovenia, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Asthma|Kidney Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
D7552C00001

P2

Recruiting

Asthma

2026-01-29

FLASH

P2

Recruiting

Asthma

2026-01-29

FLASH

P2

Active, not recruiting

Asthma

2026-01-18

jRCT2031210680

P2

Recruiting

Asthma

2024-12-31

Recent News Events

Date

Type

Title

10/15/2022

PubMed

 Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.

10/01/2021

PubMed

 Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.

08/27/2021

PubMed

 Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.

12/31/2020

News Article

 Chronic Kidney Disease (CKD) Pipeline Insight, 2020 Report Featuring 55 Key players & 10 Key Products

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions